Big pharmaceutical companies in the US are rejoicing over a new Food and Drug Administration ruling that gives them an extension of 3 years on their drug patents. Consumer groups are not exactly delighted at the change because it could cost consumers billions of dollars, since companies that make cheaper "generic" alternatives to brand-name drugs on which the patents have expired would be left out in the cold. These companies have called on the Congress to amend the law.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.